Relating price determination to disease prevalenceBMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c4615 (Published 24 August 2010) Cite this as: BMJ 2010;341:c4615
- Andrea Messori, coordinator1,
- Americo Cicchetti, professor2,
- Luigi Patregani, head3
- 1Laboratory of Pharmacoeconomics, ESTAV Centro, Health Service of Regione Toscana, 59100 Prato, Italy
- 2School of Economics, “Sacro Cuore” Catholic University, c/o Policlinico Gemelli, Roma, Italy
- 3Pharmaceutical Service, Health Service of Regione Marche, Ancona, Italy
For orphan drugs, the yearly cost per patient is inversely related to the prevalence of the disease.1 2 3 4 5 Although this relation is widely recognised qualitatively, to our knowledge, no attempt has been made to define it mathematically.
We examined the decisions made for non-cancer orphan drugs approved in Italy over the past years and developed the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial